Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.

Item
http://www.wikidata.org/entity/Q33431700
Factor Xa inhibitors for acute coronary syndromesRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceFondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data.A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary interventionCost effectiveness of treatments for non-ST-segment elevation acute coronary syndrome.Cost-effectiveness of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome in Canada (OASIS-5).Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature Review.Almanac 2011: Acute Coronary Syndromes. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology.Emerging therapies for acute coronary syndromesCost effectiveness of anticoagulation in acute coronary syndromes.Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.Cost-effectiveness of ticagrelor in acute coronary syndromes.Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery.Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010.
P2860

Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.

Item
http://www.wikidata.org/entity/Q33431700
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@ast
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@en
type
label
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@ast
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@en
prefLabel
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@ast
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@en
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Fondaparinux versus Enoxaparin ...... Investigators (OASIS-5) trial.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P698